Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2'-Fucosyllactose Supplementation in Allogeneic Bone Marrow Transplant Recipients
NCT04263597Phase 2Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Aug 2020
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of 2'-fucosyllactose in graft-versus-host disease (GVHD) and bloodstream infection (BSI) (3 arms), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoints: Number of Bloodstream Infections at Day 100, Number of Patients Able to Take 2FL at Day 30 and 3 more. Started Aug 2020; status: completed.
02
Drugs
2'-fucosyllactose
03
Conditions
graft-versus-host disease (GVHD)bloodstream infection (BSI)
Beyond the preview
Go deeper on NCT04263597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04263597.